Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745261 | 1.00 | CHEK2 (0.49) | CHEK2P2RX3P2RX2PDE4BUSP30 | |
| SCHEMBL4741775 | 0.94 | PIK3CD (0.46) | CHEK2PDE4BUSP30PIK3CD | |
| SCHEMBL4742866 | 0.94 | PIK3CD (0.46) | CHEK2PDE4BUSP30PIK3CD | |
| SCHEMBL4741773 | 0.94 | PIK3CD (0.46) | CHEK2PDE4BUSP30PIK3CD | |
| SCHEMBL4784604 | 0.90 | CHEK2 (0.51) | CHEK2P2RX3P2RX2PDE4BUSP30 | |
| SCHEMBL4742807 | 0.90 | CHEK2 (0.51) | CHEK2P2RX3P2RX2PDE4BUSP30 | |
| SCHEMBL14127666 | 0.87 | GPR119 (0.51) | CHEK2P2RX3P2RX2PDE4BALDH1A1 | |
| SCHEMBL14780123 | 0.84 | CHEK2 (0.49) | CHEK2P2RX3P2RX2PDE4BUSP30 | |
| SCHEMBL14780124 | 0.84 | CHEK2 (0.49) | CHEK2P2RX3P2RX2PDE4BUSP30 | |
| SCHEMBL16195910 | 0.84 | CHEK2 (0.49) | CHEK2P2RX3P2RX2PDE4BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | CHEK2 536/4885P2RX3 1593/4885P2RX2 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.